Mahajan Priya, Hicks John, Chintagumpala Murali, Venkatramani Rajkumar
*Department of Pediatrics, Baylor College of Medicine, Texas Children's Cancer Center, Texas Children's Hospital †Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX.
J Pediatr Hematol Oncol. 2017 Apr;39(3):e136-e139. doi: 10.1097/MPH.0000000000000732.
Myofibromas are rare fibroblastic-myofibroblastic tumors in children. Their biological behavior is unpredictable and spontaneous regressions have been described. This is a retrospective review of clinical characteristics, treatment, and outcome of children diagnosed with myofibroma between 1999 and 2013 at Texas Children's Hospital. The median age at diagnosis of 42 patients was 37 months. Approximately two thirds of the patients were male. The median length of follow-up was 50.5 months (range, 0 to 165 mo). Thirty-eight patients (90%) had solitary lesions; 19 (50%) in the head and neck, 10 (26%) in the limbs, and 9 (24%) in the trunk. Twelve patients underwent a complete surgical resection. Of the 30 patients with positive margins, only 1 had tumor progression. Two patients had multicentric involvement, and 2 patients had generalized disease with visceral involvement. One patient with generalized disease and a progressive maxillary sinus mass was treated with vinblastine and methotrexate chemotherapy followed by complete surgical resection. All patients were alive at last follow-up. Myofibromas of childhood demonstrate clinical variability, and may spontaneously regress. Positive surgical margins do not adversely affect outcome. The rare patient with progressive unresectable disease may benefit from chemotherapy.
肌纤维瘤是儿童罕见的成纤维细胞-肌成纤维细胞肿瘤。其生物学行为不可预测,且已有自发消退的报道。本文回顾性分析了1999年至2013年在德克萨斯儿童医院诊断为肌纤维瘤的儿童的临床特征、治疗及预后。42例患者诊断时的中位年龄为37个月。约三分之二的患者为男性。中位随访时间为50.5个月(范围0至165个月)。38例患者(90%)为单发病变;19例(50%)位于头颈部,10例(26%)位于四肢,9例(24%)位于躯干。12例患者接受了完整的手术切除。在30例手术切缘阳性的患者中,只有1例出现肿瘤进展。2例患者有多中心受累,2例患者有累及内脏的全身病变。1例有全身病变且上颌窦肿物进展的患者接受了长春碱和甲氨蝶呤化疗,随后进行了完整的手术切除。在最后一次随访时,所有患者均存活。儿童肌纤维瘤临床表现多样,可能会自发消退。手术切缘阳性对预后无不良影响。罕见的无法切除且病情进展的患者可能从化疗中获益。